Drugs / MDMA
last change May 2018 re-read 3 minutes ago

MDMA

Developed for
post-traumatic stress disorder
Investigated by
Resilient Pharmaceuticals

Trials 1

20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02876172 Jul 2016 → Dec 2017 post-traumatic stress disorder Resilient Pharmaceuticals Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MDMA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876172 ↗